Baidu
map

Intens Care Med:重症监护患者精神健康相关的生活质量与谵妄相关

2022-08-31 MedSci原创 MedSci原创

研究人员发现在ICU住院期间发生谵妄的ICU幸存者在入院前的精神健康相关生活质量明显较差,出院后一年的精神健康相关生活质量也显著下降。

重症监护病房(ICU)内谵妄发生在60-80%的机械通气患者和20-40%的非机械通气患者中。谵妄也被称为“意识障碍和基线认知的改变”,是一种全球性的认知障碍。谵妄被认为是ICU患者发病率和死亡率的独立预测因素。再者,ICU中谵妄的持续时间与长期认知障碍的发展有关。ICU住院期间的谵妄可能与病前精神疾病有关。

此外,ICU住院期间谵妄也可能对长期健康相关生活质量产生负面影响。

近日,危重病医学领域权威杂志Intensive Care Medicine上发表了一篇研究文章,该研究的目的是探讨ICU患者发生谵妄是否与发病前的精神生活质量相关,并影响ICU患者住院后的长期精神生活质量。

研究人员对1021名在外科ICU住院超过48小时的患者进行了一项前瞻性队列研究。研究人员采用Short-form-12量表评估了受试者入住ICU前、出院时、出院后3个月、6个月和12个月的身心生活质量。该研究的数据分析采用混合模型和逻辑回归模型的方法。

研究人员发现在ICU住院期间发生谵妄的患者报告的入院前精神生活质量低于未发生谵妄的患者(p<0.001)。此外,在ICU住院期间发生谵妄的患者与未发生谵妄的患者相比,随着时间的推移精神生活质量显著下降(p=0.035)。

在这项大型随访研究中,研究人员发现在ICU住院期间发生谵妄的ICU幸存者在入院前的精神健康相关生活质量明显较差,出院后一年的精神健康相关生活质量也显著下降。

 

原始出处:

José G. M. Hofhuis.et al.Mental health-related quality of life is related to delirium in intensive care patients.Intensive Care Medicine.2022.https://www.esicm.org/icm-search/?id=doi:10.1007/s00134-022-06841-8#article

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2039336, encodeId=f3142039336a3, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sat Feb 18 13:18:59 CST 2023, time=2023-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018163, encodeId=ef212018163f6, content=<a href='/topic/show?id=d0ca9596415' target=_blank style='color:#2F92EE;'>#重症监护患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95964, encryptionId=d0ca9596415, topicName=重症监护患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Wed Aug 02 20:18:59 CST 2023, time=2023-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551235, encodeId=16bd1551235c6, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Thu Sep 01 14:18:59 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611715, encodeId=b3591611e157c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Sep 01 14:18:59 CST 2022, time=2022-09-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2039336, encodeId=f3142039336a3, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sat Feb 18 13:18:59 CST 2023, time=2023-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018163, encodeId=ef212018163f6, content=<a href='/topic/show?id=d0ca9596415' target=_blank style='color:#2F92EE;'>#重症监护患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95964, encryptionId=d0ca9596415, topicName=重症监护患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Wed Aug 02 20:18:59 CST 2023, time=2023-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551235, encodeId=16bd1551235c6, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Thu Sep 01 14:18:59 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611715, encodeId=b3591611e157c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Sep 01 14:18:59 CST 2022, time=2022-09-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2039336, encodeId=f3142039336a3, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sat Feb 18 13:18:59 CST 2023, time=2023-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018163, encodeId=ef212018163f6, content=<a href='/topic/show?id=d0ca9596415' target=_blank style='color:#2F92EE;'>#重症监护患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95964, encryptionId=d0ca9596415, topicName=重症监护患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Wed Aug 02 20:18:59 CST 2023, time=2023-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551235, encodeId=16bd1551235c6, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Thu Sep 01 14:18:59 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611715, encodeId=b3591611e157c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Sep 01 14:18:59 CST 2022, time=2022-09-01, status=1, ipAttribution=)]
    2022-09-01 bioon6
  4. [GetPortalCommentsPageByObjectIdResponse(id=2039336, encodeId=f3142039336a3, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sat Feb 18 13:18:59 CST 2023, time=2023-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018163, encodeId=ef212018163f6, content=<a href='/topic/show?id=d0ca9596415' target=_blank style='color:#2F92EE;'>#重症监护患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95964, encryptionId=d0ca9596415, topicName=重症监护患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Wed Aug 02 20:18:59 CST 2023, time=2023-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551235, encodeId=16bd1551235c6, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Thu Sep 01 14:18:59 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611715, encodeId=b3591611e157c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Sep 01 14:18:59 CST 2022, time=2022-09-01, status=1, ipAttribution=)]

相关资讯

Stroke:谵妄对脑出血患者预后的影响

大多数ICH患者的急性谵妄会在出院后消退,这与持续性谵妄患者相比具有更好的结局。谵妄对结局的影响可以通过急性后康复进一步减轻。

JAMA Surg:多重干预措施用于普外科及骨科高龄患者术后谵妄的预防

多方面的预防干预措施可显著降低骨科以及普外科老年患者术后谵妄风险

JNNP:谵妄与痴呆风险,一项对12949名患者的队列研究

谵妄和痴呆是老年人认知障碍的两个最常见原因,但对其相互关系了解甚少。痴呆的特征是不可逆转的渐进性认知下降。这与压力有关。在英国,痴呆症的社会负担为350亿英镑,其中三分之二由痴呆症患者及其家人承担。

JAMA:局部 vs 全身麻醉对65岁以上老年髋部骨折患者术后谵妄风险的影响

对于65岁以上需接受手术治疗的髋部骨折患者,局部麻醉不会降低患者术后谵妄风险

JAMA Intern Med:患者生命体征实时预测工具用于识别病情稳定患者

住院患者生命体征实时预测工具可以帮助医生识别临床状态稳定患者,减少不必要查房,提高患者睡眠质量

Baidu
map
Baidu
map
Baidu
map